TMQLB Versus TPVB for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery
- Conditions
- Nerve Block, Nephrectomy, Analgesia
- Interventions
- Procedure: TPVBProcedure: TMQLB group 2Procedure: TMQLB group 1
- Registration Number
- NCT03414281
- Lead Sponsor
- Cui Xulei
- Brief Summary
This trial is a prospective, randomized, single-center, open-label, parallel-arm, blinded-analysis trial, the objective of which is to evaluate the effect of transmuscular quadratus lumborum block (TMQLB) in the pain relief and quality of recovery in laparoscopic renal surgery compared with thoracic paravertebral block (TPVB).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 30
- 17~80 years of age;
- American Society of Anesthesiologists physical status I-III;
- undergoing laparoscopic nephrectomy.
- have a known allergy to the anesthetics being used;
- infection at injection site
- coagulopathy or history of anticoagulants use
- chronic analgesics consumption or history of substance abuse
- inability to properly describe postoperative pain or recovery to investigators (e.g., language barrier, neuropsychiatric disorder).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TPVB group TPVB 0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach. TMQLB group 2 TMQLB group 2 0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach. TMQLB group 1 TMQLB group 1 0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
- Primary Outcome Measures
Name Time Method mean VAS of the first postoperative 24 hours within the first 24 postoperative hours VAS is an internationally recognized pain scale with 11 points ranging from 0 to 10 points, with 0 defined as no pain and 10 defined as the worst pain imaginable. The VAS will be registered at 0, 2, 4, 8, 12, 24 hours after the surgery, and the primary outcome will be calculated as the mean VAS scores measured at these time point.
- Secondary Outcome Measures
Name Time Method nausea score at 0, 2, 4, 8, 12, 24 and 48 hours after the surgery; pruritus score at 0, 2, 4, 8, 12, 24 and 48 hours after the surgery; quality of recovery evaluated by the self-assessment 15-item quality of recovery (QoR) scale at 3 days and 5 days after the sugery QoR is a 15-item questionnaire which will score on a scale of 0-10 pertaining to patient's comfort, support system, pain, well-being, and ability to carry out daily activities, where 0 indicates none of the time and 10 indicates all of the time
time of recovery of bowel movement after the surgery defined as the time to first flatus
ambulation time after the surgery time to patient's first walking after the surgery
cumulative morphine consumption at 0, 2,4, 8, 12, 24 ,48, 72hours and 7 day after the surgery morphine consumption will be registered at 0, 2, 4, 8, 12, 24, 48, 72 hours and 7 days after the surgery and will be calculated as the sum of the values
long-term pain control at 48, 72 and 7 days after the surgery evaluated by VAS at 48, 72 hours and 7 days after the surgery
dermatomal distribution of sensory loss 10, 20, 30 and 40 minutes after the intervention evaluated at 10, 20, 30 and 40 minutes after the intervention with pinprick test using Von Frey filaments
postoperative length of hospital stay after the surgery time to patient's discharge
patient satisfaction with anesthesia at 48 hours after the surgery evaluated with the Chinese version of Bauer questionnaire at 48 hours after the surgery
Trial Locations
- Locations (1)
Xulei CUI
🇨🇳Beijing, Beijing, China